Discover and read the best of Twitter Threads about #THT2022
Most recents (4)
Fantastic presentation on Physiological Phenotyping of HFpEF by @HFpEF #THT2022 @crfheart
@ShelleyZieroth @AHajduczok @a_h_ghoneem
@karanpdesai @KevinShahMD
@GiuseppeGalati_ @ShashankSinhaMD @docbhardwaj
@crfheart
#THT2022
@ShelleyZieroth @AHajduczok @a_h_ghoneem
@karanpdesai @KevinShahMD
@GiuseppeGalati_ @ShashankSinhaMD @docbhardwaj
@crfheart
#THT2022
Phenotyping #HFpEF: beyond EF and Future treatment of obese HFpEF
@HFpEF @JJheart_doc @JavedButler1 @NirUrielMD @SantosGallegoMD @mmamas1973 @pabeda1 @VietHeartPA @docbhardwaj @hvanspall @ShelleyZieroth @aayshacader @AndrewJSauer @crfheart @rachkataria
@HFpEF @JJheart_doc @JavedButler1 @NirUrielMD @SantosGallegoMD @mmamas1973 @pabeda1 @VietHeartPA @docbhardwaj @hvanspall @ShelleyZieroth @aayshacader @AndrewJSauer @crfheart @rachkataria
Interesting case of 74 yr old women with BMI 46 kg/m2 with HFpEF
HFpEF: A BNP deficiency syndrome @HFpEF #THT2022 @crfheart @mmamas1973 @pabeda1 @VietHeartPA @docbhardwaj @hvanspall @ShelleyZieroth @aayshacader @AndrewJSauer @crfheart @rachkataria @rachkataria @DrMarthaGulati
HFpEF: A BNP deficiency syndrome @HFpEF #THT2022 @crfheart @mmamas1973 @pabeda1 @VietHeartPA @docbhardwaj @hvanspall @ShelleyZieroth @aayshacader @AndrewJSauer @crfheart @rachkataria @rachkataria @DrMarthaGulati
Join now at #THT2022 as @HFpEF describes the results of the REDUCE HF-LAP II trial: the largest contemporary HFpEF device based trial.
Not the exclusion criteria for patients that may not tolerate a right sided volume load were defined by resting RA pressure, TR severity and PVR
Not the exclusion criteria for patients that may not tolerate a right sided volume load were defined by resting RA pressure, TR severity and PVR
This was a sick population with a median resting PCWP > 18. Meticulous definition of HFpEF with Exercise hemodynamics
The LA strain was quite low in both arms and could that affect who would respond @RBPatelMD?
The LA strain was quite low in both arms and could that affect who would respond @RBPatelMD?
To the results: as predicted there was no change in incidence of CVD ☠️ btw sham and IASD, but there was also not a difference in 🏥.
What accounts for this result?
This was a sick population overall and wonder if those w/ low LA/RA reservoir affected likelihood to respond
What accounts for this result?
This was a sick population overall and wonder if those w/ low LA/RA reservoir affected likelihood to respond
Join now as Dr. Mann gives a keynote on HF in 2022 in the era of SGLT2i #THT2022
“Predicting the future isn’t what it used to be” - Yogi Berra
In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists
“Predicting the future isn’t what it used to be” - Yogi Berra
In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists
Followed by @NirUrielMD talking about the future of HF and pointing out this fantastic paper from @HRRosenblum on a device-based approach to ADHF w/ the DRI2️⃣P2️⃣S approach
Read paper here: ahajournals.org/doi/full/10.11…
@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok
Read paper here: ahajournals.org/doi/full/10.11…
@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok
What a whirlwind tour by @GreggWStone on how the sausage gets made with HF device clinical trials
Look at all the factors: critical background on understanding how the evidence forms for the science we apply at the bedside
@mvaduganathan @FudimMarat @vbluml @SJGreene_md
Look at all the factors: critical background on understanding how the evidence forms for the science we apply at the bedside
@mvaduganathan @FudimMarat @vbluml @SJGreene_md
Very insightful discussion on Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life by @JavedButler1 in #THT2022
@LindenfeldJoa @TheHeartBeat3 @LiviuKlein @HFpEF @RyanTedfordMD @GreggWStone @SKumar_UTHealth @gtsayer @SrihariNaiduMD @purviparwani
@LindenfeldJoa @TheHeartBeat3 @LiviuKlein @HFpEF @RyanTedfordMD @GreggWStone @SKumar_UTHealth @gtsayer @SrihariNaiduMD @purviparwani
📌SGLT2i clinical benefits is seen irrespective of baseline health status
#SGLT2i improve health status and quality of life early and sustained in both patients with #HFrEF and #HFpEF
@JavedButler1
@ShelleyZieroth @SeguraCardio @docbhardwaj @docbhardwaj @KevinShahMD #THT2022
#SGLT2i improve health status and quality of life early and sustained in both patients with #HFrEF and #HFpEF
@JavedButler1
@ShelleyZieroth @SeguraCardio @docbhardwaj @docbhardwaj @KevinShahMD #THT2022
#Canagliflozin Improves Quality of Life in HF Patients in #CHIEF-HF
One of the strengths of CHIEF-HF is the diversity of participants, noting that 14% of patients were Black and 45% were female @JavedButler1 #THT2022 @JamalRanaMD @crfheart @SantosGallegoMD @ShelleyZieroth
One of the strengths of CHIEF-HF is the diversity of participants, noting that 14% of patients were Black and 45% were female @JavedButler1 #THT2022 @JamalRanaMD @crfheart @SantosGallegoMD @ShelleyZieroth
